How can Angle Plc help Myriad Genetics and SOPHiA GENETICS?23 Sep 2025 14:20
Angle plc's Parsortix system can help Myriad Genetics and SOPHiA GENETICS by enabling their genomic analysis platforms to use intact circulating tumor cells (CTCs) harvested from a simple blood draw
. This expands the capabilities of Myriad and SOPHiA from primarily tissue-based diagnostics to a less invasive liquid biopsy approach.
How Angle helps Myriad Genetics
In August 2025, Angle plc and Myriad Genetics announced a collaboration to explore using blood-based testing for cancer patients. This partnership aims to overcome the limitations of traditional tissue biopsies.
Access to intact CTCs: Myriad typically relies on tissue-based assays for cancer diagnostics. Angle's Parsortix system allows Myriad to capture intact, live CTCs from a blood sample, which can be analyzed for molecular information.
Expansion of diagnostic tests: The collaboration seeks to extend Myriad's tissue-based companion diagnostic tests to work with a simple blood test. This would expand the reach of their tests, potentially improving access to actionable genomic data for more patients.
Less invasive monitoring: A blood-based liquid biopsy is a less invasive alternative to a solid tissue biopsy, which can be difficult or impossible for some patients. This allows for repeated testing to monitor a cancer's evolution over time.
How Angle could help SOPHiA GENETICS
Though not in a direct announced partnership with Angle, SOPHiA GENETICS could potentially benefit from using the Parsortix system to enhance its data-driven medicine (DDM) platform.
Integration with the SOPHiA DDM platform: The SOPHiA DDM platform analyzes complex data from multiple sources to provide insights for cancer and rare disorders. Angle's Parsortix system could serve as a valuable input, supplying the DDM platform with high-quality genomic data from intact CTCs.
Enabling multi-modal analysis: SOPHiA GENETICS emphasizes multimodal analysis, which involves combining different data types for a more comprehensive picture. By providing a source for robust CTC data, Angle could enable SOPHiA to integrate genomic information from liquid biopsies with other data, such as radiomics and tissue sequencing.
Complementing liquid biopsy efforts: SOPHiA has an innovative companion diagnostic (CDx) offering in liquid biopsy. Capturing intact CTCs with the Parsortix system would complement their existing liquid biopsy technology, which focuses on circulating tumor DNA (ctDNA). Analyzing both CTCs and ctDNA provides a more complete view of a tumor's biology.
Sign In
Follow the stocks
